Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) EBITDA
Vertex Pharmaceuticals Incorporated's EBITDA for fiscal 2025 was $4.4B, compared with −$25.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.0B. Over the past ten years it has ranged from −$404.5M (fiscal 2015) to $4.5B (fiscal 2022); the current reading is higher than 91% of that period. Vertex Pharmaceuticals Incorporated ranks 1st of 600 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $4.4B | — |
| FY2024 | −$25.7M | — |
| FY2023 | $4.0B | (9.93%) |
| FY2022 | $4.5B | 53.24% |
| FY2021 | $2.9B | (1.96%) |
| FY2020 | $3.0B | 127.37% |
| FY2019 | $1.3B | 84.35% |
| FY2018 | $707.6M | 283.22% |
| FY2017 | $184.6M | 158.84% |
| FY2016 | $71.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.3B | 9.16% |
| Mar 2026 | $1.2B | (5.36%) |
| Dec 2025 | $1.3B | 1.73% |
| Sep 2025 | $1.2B | 3.11% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $5.0B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.4B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.1B |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
| MRNA Moderna, Inc. compare | −$3.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement